Copyright Reports & Markets. All rights reserved.

(Post-pandemic Era)-Global At-Home Drug of Abuse (DOA) Testing Market Segment Research Report 2022

Request for Sample of this report
Buy now

Table of Contents

    Global At-Home Drug of Abuse (DOA) Testing Market Segment Research Report 2022

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global At-Home Drug of Abuse (DOA) Testing Market by Value
          • 2.2.1 Global At-Home Drug of Abuse (DOA) Testing Revenue by Type
          • 2.2.2 Global At-Home Drug of Abuse (DOA) Testing Market by Value (%)
        • 2.3 Global At-Home Drug of Abuse (DOA) Testing Market by Production
          • 2.3.1 Global At-Home Drug of Abuse (DOA) Testing Production by Type
          • 2.3.2 Global At-Home Drug of Abuse (DOA) Testing Market by Production (%)

        3. The Major Driver of At-Home Drug of Abuse (DOA) Testing Industry

        • 3.1 Historical & Forecast Global At-Home Drug of Abuse (DOA) Testing Demand
        • 3.2 Largest Application for At-Home Drug of Abuse (DOA) Testing (2018-2028)
        • 3.3 The Major Downstream Company in China Market 2022

        4. Global and Regional At-Home Drug of Abuse (DOA) Testing Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2022)
        • 4.2 Regional Market Share in Terms of Revenue (2018-2022)
        • 4.3 Concentration Ratio (CR5& CR10) of At-Home Drug of Abuse (DOA) Testing Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US At-Home Drug of Abuse (DOA) Testing Production, Demand (2018-2028)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        6. Europe At-Home Drug of Abuse (DOA) Testing Production, Demand (2018-2028)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        7. China At-Home Drug of Abuse (DOA) Testing Production, Demand (2018-2028)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        8. Japan At-Home Drug of Abuse (DOA) Testing Production, Demand (2018-2028)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        9. India At-Home Drug of Abuse (DOA) Testing Production, Demand (2018-2028)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        10. Korea At-Home Drug of Abuse (DOA) Testing Production, Demand (2018-2028)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        11. Southeast Asia At-Home Drug of Abuse (DOA) Testing Production, Demand (2018-2028)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        12. Global At-Home Drug of Abuse (DOA) Testing Average Price Trend

        • 12.1 Market Price for Each Type of At-Home Drug of Abuse (DOA) Testing in US (2018-2022)
        • 12.2 Market Price for Each Type of At-Home Drug of Abuse (DOA) Testing in Europe (2018-2022)
        • 12.3 Market Price for Each Type of At-Home Drug of Abuse (DOA) Testing in China (2018-2022)
        • 12.4 Market Price for Each Type of At-Home Drug of Abuse (DOA) Testing in Japan (2018-2022)
        • 12.5 Market Price for Each Type of At-Home Drug of Abuse (DOA) Testing in India (2018-2022)
        • 12.6 Market Price for Each Type of At-Home Drug of Abuse (DOA) Testing in Korea (2018-2022)
        • 12.7 Market Price for Each Type of At-Home Drug of Abuse (DOA) Testing in Southeast Asia (2018-2022)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 At-Home Drug of Abuse (DOA) Testing Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Post-pandemic Era
        • 13.5 Technology Trends of At-Home Drug of Abuse (DOA) Testing

        14. At-Home Drug of Abuse (DOA) Testing Competitive Landscape

        • 14.1 UCP Biosciences
          • 14.1.1 UCP Biosciences Company Profiles
          • 14.1.2 UCP Biosciences Product Introduction
          • 14.1.3 UCP Biosciences At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.1.4 Strategic initiatives
        • 14.2 Orient New Life Medical
          • 14.2.1 Orient New Life Medical Company Profiles
          • 14.2.2 Orient New Life Medical Product Introduction
          • 14.2.3 Orient New Life Medical At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.2.4 Strategic initiatives
        • 14.3 Express Diagnostics Int’l
          • 14.3.1 Express Diagnostics Int’l Company Profiles
          • 14.3.2 Express Diagnostics Int’l Product Introduction
          • 14.3.3 Express Diagnostics Int’l At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.3.4 Strategic initiatives
        • 14.4 Assure Tech (Hangzhou)
          • 14.4.1 Assure Tech (Hangzhou) Company Profiles
          • 14.4.2 Assure Tech (Hangzhou) Product Introduction
          • 14.4.3 Assure Tech (Hangzhou) At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.4.4 Strategic initiatives
        • 14.5 Psychemedics Corporation
          • 14.5.1 Psychemedics Corporation Company Profiles
          • 14.5.2 Psychemedics Corporation Product Introduction
          • 14.5.3 Psychemedics Corporation At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.5.4 Strategic initiatives
        • 14.6 Confirm BioSciences
          • 14.6.1 Confirm BioSciences Company Profiles
          • 14.6.2 Confirm BioSciences Product Introduction
          • 14.6.3 Confirm BioSciences At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.6.4 Strategic initiatives
        • 14.7 Phamatech
          • 14.7.1 Phamatech Company Profiles
          • 14.7.2 Phamatech Product Introduction
          • 14.7.3 Phamatech At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.7.4 Strategic initiatives
        • 14.8 Home Health (U.K.) Ltd.
          • 14.8.1 Home Health (U.K.) Ltd. Company Profiles
          • 14.8.2 Home Health (U.K.) Ltd. Product Introduction
          • 14.8.3 Home Health (U.K.) Ltd. At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.8.4 Strategic initiatives
        • 14.9 Quest Products
          • 14.9.1 Quest Products Company Profiles
          • 14.9.2 Quest Products Product Introduction
          • 14.9.3 Quest Products At-Home Drug of Abuse (DOA) Testing Sales, Revenue (2018-2022)
          • 14.9.4 Strategic initiatives

        15. Conclusion

          16. Methodology and Data Source

          Summary

          The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

          2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

          According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

          Beijing Yanjing Bizhi Information Consulting Co., Ltd. （XYZResearch）released the 《(Post-pandemic Era)-Global At-Home Drug of Abuse (DOA) Testing Market Segment Research Report 2022》, which aims to sort out the development status and trends of the At-Home Drug of Abuse (DOA) Testing industry at home and abroad, estimate the overall market scale of the At-Home Drug of Abuse (DOA) Testing industry and the market share of major countries, At-Home Drug of Abuse (DOA) Testing industry, and study and judge the downstream market demand of At-Home Drug of Abuse (DOA) Testing through systematic research, Analyze the competition pattern of At-Home Drug of Abuse (DOA) Testing, so as to help solve the pain points of various stakeholders in At-Home Drug of Abuse (DOA) Testing industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

          Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of At-Home Drug of Abuse (DOA) Testing Market by XYZResearch Include
          USA
          Europe
          China
          Japan
          India
          Korea
          Southeast Asia
          Competitive Analysis; Who are the Major Players in At-Home Drug of Abuse (DOA) Testing Market?
          UCP Biosciences
          Orient New Life Medical
          Express Diagnostics Int’l
          Assure Tech (Hangzhou)
          Psychemedics Corporation
          Confirm BioSciences
          Phamatech
          Home Health (U.K.) Ltd.
          Quest Products
          Major Type of At-Home Drug of Abuse (DOA) Testing Covered in XYZResearch report:
          Test Cups
          Test Dip Cards
          Test Strips
          Others
          Application Segments Covered in XYZResearch Market
          Urine
          Saliva
          Hair
          Others

          For any other requirements, please feel free to contact us and we will provide you customized report.
          Buy now